Eosinophilic esophagitis: treatment with oral viscous budesonide

Central Laboratory of Super-Pharm, Yarkon Center, Petach-Tikvah, Israel.
International Journal of Pharmaceutical Compounding 10/2012; 16(4):288-93.
Source: PubMed


Eosinophilic esophagitis is a clinicopathologic disease isolated to the esophagus. It is caused by immunologic reactions to ingested and inhaled allergans. Symptoms include regurgitation, vomiting, pain, anorexia, and dysphagia. Endoscopy with biopsy is currently the only reliable diagnostic test for eosinophilic esophagitis. The disease should remit with treatments of dietary exclusion, topical corticosteroids, or both. Oral viscous budesonide is one of the promising options of topical corticosteroid to treat eosinophilic esophagitis. Since there are no commercial medicines of oral viscous budesonide, it is solely a compounded medication. This article briefly discusses the properties of the disease and covers a few compounding possibilities to oral viscous budesonide.

Download full-text


Available from: Eyal Zur, Oct 28, 2014